Aceto Corp. (ACET)
Shares of ACET climbed more than 10% in after-hours trading Thursday as the company delivered its strongest earnings quarter in its history, driven by strong growth in its Human Health segment
For its fourth quarter fiscal 2015, posted net sales of $146.6 million, a 5.0% increase year over year, and non-GAAP adjusted net income of $14.0 million, or $0.48 per diluted share, compared to non-GAAP adjusted net income of $7.6 million, or $0.26 per diluted share in the same period the prior year.
ACET expects to achieve (at current exchange rates) mid-single digit revenue growth and low-double digit net income growth in fiscal 2016.
ACET‘s Board of Directors has declared a regular quarterly dividend of $0.06 per common share. This quarterly cash dividend will be distributed on October 2, 2015 to shareholders of record as of September 21, 2015.
ACET is a global leader in the marketing, sale and distribution of products for Human Health (finished dosage form generics and nutraceutical products), Pharmaceutical Ingredients (pharmaceutical intermediates and active pharmaceutical ingredients), and Performance Chemicals (specialty chemicals and agricultural protection products).
More about Aceto Corp. (ACET) at www.aceto.com
ZS Pharma, Inc. (ZSPH)
ZSPH shares continued its positive momentum in the extended session Thursday after the company confirmed that it has participated in preliminary discussions with Actelion Ltd. regarding a potential strategic transaction. According to ZSPH, these discussions may or may not lead to any transaction
Bloomberg reported earlier Thursday that the two companies had discussed a deal that would value ZSPH at $2.5 billion.
ZSPH recently reported a net loss of ($32.6) million, or ($1.30) per diluted share in its second quarter 2015.
ZSPH is a biopharmaceutical company. Its lead therapeutic candidate, ZS-9 (sodium zirconium cyclosilicate), is an investigational treatment for hyperkalemia that has been submitted to the FDA for potential approval for the treatment of hyperkalemia. ZSPH is also pursuing the discovery of additional drug candidates that utilize its novel selective ion-trap technology for the treatment of kidney and liver diseases.
More about ZS Pharma, Inc. (ZSPH) at www.zspharma.com.
Crown Equity Holdings Inc. (CRWE)
CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
The company is currently developing its CRWE WORLD ( www.crweworld.com ), a community targeted platform which goal is to be a one-stop shop for the various needs of online consumers in a range of marketing specialties like Real Estate, Coupons & Deals, Business Directory and more
CRWE WORLD’s business model is based on selling advertising to businesses targeting their marketing message locally, nationally, internationally and also to target potential clients for an specific location, such as within a certain zip code.
The company’s CRWE Real Estate ( www.CRWERealEstate.com ) is expected to be integrated in all the CRWE WORLD Network. It will allow people to submit their listings for exposure to visitors searching for homes.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE PR Finance www.finance.crwe-pr.com/disclaimer